Tectonic Therapeutic Inc
TECX15.640USD
+0.580+3.85%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
292.66MMarket Cap
LossP/E TTM
More Details of Tectonic Therapeutic Inc Company
Tectonic Therapeutic, Inc. is a biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead program, TX000045 (TX45), is an Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). Its second program addresses Hereditary Hemorrhagic Telangiectasia (HHT).
Company Info
Ticker SymbolTECX
Company nameTectonic Therapeutic Inc
IPO dateJun 21, 2018
CEODr. Alise S. Reicin, M.D.
Number of employees51
Security typeOrdinary Share
Fiscal year-endJun 21
Address490 Arsenal Way
CityWATERTOWN
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02472
Phone13396663320
Websitehttps://tectonictx.com/
Ticker SymbolTECX
IPO dateJun 21, 2018
CEODr. Alise S. Reicin, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Alise S. Reicin, M.D.
Dr. Alise S. Reicin, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
290.25K
-0.30%
Dr. Peter Mcnamara, Ph.D.
Dr. Peter Mcnamara, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
19.53K
+344.82%
Dr. Praveen P. Tipirneni, M.D.
Dr. Praveen P. Tipirneni, M.D.
Independent Director
Independent Director
3.04K
--
Dr. Timothy A. (Tim) Springer, Ph.D.
Dr. Timothy A. (Tim) Springer, Ph.D.
Independent Director
Independent Director
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
IR Contact Officer
IR Contact Officer
--
--
Mr. Daniel Lochner
Mr. Daniel Lochner
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Terrance G. (Terry) Mcguire
Mr. Terrance G. (Terry) Mcguire
Independent Director
Independent Director
--
--
Dr. Marc Schwabish, Ph.D.
Dr. Marc Schwabish, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Phillip B. (Phil) Donenberg
Mr. Phillip B. (Phil) Donenberg
Independent Director
Independent Director
--
--
Mr. Stefan Vitorovic
Mr. Stefan Vitorovic
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Alise S. Reicin, M.D.
Dr. Alise S. Reicin, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
290.25K
-0.30%
Dr. Peter Mcnamara, Ph.D.
Dr. Peter Mcnamara, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
19.53K
+344.82%
Dr. Praveen P. Tipirneni, M.D.
Dr. Praveen P. Tipirneni, M.D.
Independent Director
Independent Director
3.04K
--
Dr. Timothy A. (Tim) Springer, Ph.D.
Dr. Timothy A. (Tim) Springer, Ph.D.
Independent Director
Independent Director
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
IR Contact Officer
IR Contact Officer
--
--
Mr. Daniel Lochner
Mr. Daniel Lochner
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Springer Timothy A
23.63%
Fidelity Management & Research Company LLC
14.97%
Deep Track Capital LP
7.49%
TAS Partners, L.L.C.
7.39%
EcoR1 Capital, LLC
5.00%
Other
41.52%
Shareholders
Shareholders
Proportion
Springer Timothy A
23.63%
Fidelity Management & Research Company LLC
14.97%
Deep Track Capital LP
7.49%
TAS Partners, L.L.C.
7.39%
EcoR1 Capital, LLC
5.00%
Other
41.52%
Shareholder Types
Shareholders
Proportion
Individual Investor
27.31%
Investment Advisor
26.93%
Hedge Fund
23.57%
Corporation
10.91%
Investment Advisor/Hedge Fund
10.24%
Venture Capital
2.73%
Research Firm
1.30%
Pension Fund
0.13%
Bank and Trust
0.07%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
182
18.65M
99.86%
+1.68M
2025Q1
184
18.15M
106.94%
+1.93M
2024Q4
153
13.88M
94.13%
+369.61K
2024Q3
148
13.13M
89.69%
+166.42K
2024Q2
151
11.92M
81.47%
+8.19M
2024Q1
179
2.57M
67.87%
-1.12M
2023Q4
200
2.14M
56.67%
-1.83M
2023Q3
236
2.28M
60.58%
-1.25M
2023Q2
243
1.76M
47.84%
-1.94M
2023Q1
262
2.00M
54.58%
-1.52M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Springer Timothy A
4.42M
23.68%
+196.29K
+4.64%
Apr 11, 2025
Fidelity Management & Research Company LLC
2.80M
14.99%
+1.28M
+84.63%
Mar 31, 2025
Deep Track Capital LP
1.40M
7.51%
--
--
Mar 31, 2025
TAS Partners, L.L.C.
1.38M
7.41%
+412.50K
+42.52%
Apr 03, 2025
EcoR1 Capital, LLC
935.12K
5.01%
+85.98K
+10.13%
Mar 31, 2025
Farallon Capital Management, L.L.C.
853.05K
4.57%
+140.00K
+19.63%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
186.07K
1%
+17.21K
+10.20%
Mar 31, 2025
Polaris Partners
657.98K
3.52%
-500.00K
-43.18%
Apr 03, 2025
The Vanguard Group, Inc.
361.17K
1.93%
+120.00
+0.03%
Mar 31, 2025
5AM Ventures
511.66K
2.74%
-85.00K
-14.25%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 18, 2024
Merger
12→1
Jun 18, 2024
Merger
12→1
Jun 18, 2024
Merger
12→1
Jun 18, 2024
Merger
12→1
Date
Type
Ratio
Jun 18, 2024
Merger
12→1
Jun 18, 2024
Merger
12→1
Jun 18, 2024
Merger
12→1
Jun 18, 2024
Merger
12→1
